文献速递自身免疫性与大疱性皮肤病

比较利妥昔单抗治疗的早期与晚期复发天疱疮患者的前瞻性研究

A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
PubMed 文献 · J Am Acad Dermatol · 2018-01-31

这项前瞻性研究纳入19例天疱疮患者(14例寻常型、5例落叶型),接受1个周期利妥昔单抗治疗并随访26个月。早期复发组(5例)基线抗桥粒芯糖蛋白1指数为705.72,显著高于晚期复发组(6例)的210.4(P=0.0014),且基线抗桥粒芯糖蛋白1指数与复发时间呈显著负相关(r=-0.777,P=0.00009)。

要点

  • 早期复发(12个月内)患者基线抗桥粒芯糖蛋白1指数显著高于晚期复发(24个月后)患者。
  • 基线抗桥粒芯糖蛋白1指数与复发时间呈显著负相关(r=-0.777,P=0.00009)。
  • 作者认为高基线抗桥粒芯糖蛋白1指数患者利妥昔单抗治疗后初始12个月可能需密切随访。

核心结论

  • 基线抗桥粒芯糖蛋白1指数高的患者复发更早,利妥昔单抗治疗后初始12个月密切随访可能重要。
  • 作者认为这些患者利妥昔单抗治疗后初始12个月可能需要维持剂量利妥昔单抗。

研究设计与样本

  • 前瞻性研究,纳入19例天疱疮患者(14例寻常型天疱疮、5例落叶型天疱疮)。
  • 测量基线疾病评分、自身抗体水平及CD20+细胞百分比,患者接受1个周期利妥昔单抗治疗并随访26个月。

主要发现

  • 早期复发组(n=5)复发时间为6至11个月,晚期复发组(n=6)复发时间为24至26个月。
  • 早期复发组平均基线抗桥粒芯糖蛋白1指数为705.72,晚期复发组为210.4,差异显著(P=0.0014)。
  • 基线抗桥粒芯糖蛋白1指数与复发时间呈显著负相关(r=-0.777,P=0.00009)。

局限性

  • 落叶型天疱疮患者数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rituximab (RTX) is an effective therapy for patients with pemphigus; however, the therapy does not prevent relapse. OBJECTIVES: To compare early relapsing patients (before 12 months) and late relapsing patients (after 24 months) following RTX therapy. METHOD: In this prospective study, 19 patients were enrolled (14 with pemphigus vulgaris and 5 with pemphigus foliaceus). The baseline disease score, autoantibody levels, and percentage of CD20+ cells of patients with pemphigus were measured. Patients received 1 cycle of RTX and were followed for 26 months. RESULTS: Among early relapsing patients (n = 5), the time to relapse was 6 to 11 months. Among late relapsing patients (n = 6), the time to relapse was 24 to 26 months. A significant difference was observed in the mean baseline anti-desmoglein 1 (DSG1) index between early relapsing (705.72) and late relapsing patients (210.4) (P = .0014). A significant negative correlation was found between the baseline anti-DSG1 index and time to relapse (r = -0.777, P = .00009). LIMITATIONS: The small number of patients with pemphigus foliaceus. CONCLUSIONS: Because patients with high baseline anti-DSG1 indices relapsed earlier, it may be important to follow these patients closely for the initial 12 months after RTX therapy. These patients may require a maintenance RTX dose during the first 12 months after RTX therapy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018. PMID: 29408700. doi:10.1016/j.jaad.2018.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。